Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals

This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and blood HbA1c levels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c (by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1β and TNF-α levels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties.

• Publication year

  2014

• Venue

  Mediators of Inflammation

• Publication date

  2014-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2014/538737PMID 24817793PMCID 4000968
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.

  2014cited by this paper
• Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin‐resistant rats

  2013cited by this paper
• Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.

  2013cited by this paper
• Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物)

  2013cited by this paper
• Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

  2013cited by this paper
• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  2012cited by this paper
• GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.

  2012cited by this paper
• Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood–retinal barrier in a type 2 diabetes animal model

  2012cited by this paper
• Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity

  2012cited by this paper
• Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs) – induced apoptosis

  2012cited by this paper
• Inflammation in Diabetic Nephropathy

  2012cited by this paper
• Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats

  2012cited by this paper
• Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.

  2011cited by this paper
• Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.

  2011cited by this paper
• Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

  2011cited by this paper
• Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome.

  2011cited by this paper
• Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

  2011influential reference
• Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries

  2011cited by this paper
• Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells.

  2010cited by this paper
• Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

  2010cited by this paper
• DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

  2010cited by this paper
• Exendin-4 Prevents c-Jun N-Terminal Protein Kinase Activation by Tumor Necrosis Factor- (cid:1) (TNF (cid:1) ) and Inhibits TNF (cid:1) -Induced Apoptosis in Insulin-Secreting Cells

  2010cited by this paper
• New paradigms in cell death in human diabetic nephropathy.

  2010cited by this paper
• Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis

  2009cited by this paper
• Pathogenic perspectives for the role of inflammation in diabetic nephropathy.

  2009cited by this paper
• Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats.

  2009cited by this paper
• Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway

  2009cited by this paper
• The role of reactive oxygen species in apoptosis of the diabetic kidney

  2009cited by this paper
• GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells

  2009cited by this paper
• The pathogenesis of diabetic nephropathy

  2008cited by this paper
• Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).

  2008cited by this paper
• Anti-apoptotic Action of Exendin-4 in INS-1 Beta Cells: Comparative Protein Pattern Analysis of Isolated Mitochondria

  2008cited by this paper
• Diabetic Nephropathy: Mechanisms of Renal Disease Progression

  2008cited by this paper
• Proteinuria in diabetic kidney disease: a mechanistic viewpoint.

  2008cited by this paper
• Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

  2008cited by this paper
• Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis

  2008cited by this paper
• Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes

  2008cited by this paper
• Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

  2007cited by this paper
• Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation

  2007cited by this paper
• The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice.

  2007cited by this paper
• The role of protein kinase C activation in diabetic nephropathy.

  2007cited by this paper
• Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.

  2006cited by this paper
• Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

  2006cited by this paper
• Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.

  2006cited by this paper
• DPP‐4 inhibitors and their potential role in the management of type 2 diabetes

  2006cited by this paper
• The biology of incretin hormones.

  2006cited by this paper
• Diabetes, Inflammation, Proinflammatory Cytokines, and Diabetic Nephropathy

  2006cited by this paper
• Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions.

  2005cited by this paper
• Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression*

  2005cited by this paper
• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function.

  2005cited by this paper
• Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats

  2005cited by this paper
• Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes.

  2005cited by this paper
• Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.

  2004cited by this paper
• Pathogenesis of Diabetic Nephropathy

  2004cited by this paper
• Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients

  2003cited by this paper
• High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism.

  2003cited by this paper
• Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy.

  2003cited by this paper
• Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.

  2003cited by this paper
• Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

  2002influential reference
• Sid knocks them out

  2002cited by this paper
• Activation of tubular epithelial cells in diabetic nephropathy.

  2002cited by this paper
• Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

  2002cited by this paper
• Taurine Prevents Apoptosis Induced by High Ambient Glucose in Human Tubule Renal Cells

  2002influential reference
• Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

  2002cited by this paper
• Transcription factor-kappa B (NF-kappa B) and renal disease.

  2001cited by this paper
• Progression of diabetic nephropathy.

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Aldose reductase and the role of the polyol pathway in diabetic nephropathy.

  2000cited by this paper
• Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.

  2000cited by this paper
• Rodent models of nephropathy associated with type II diabetes.

  1999cited by this paper
• Progression of Diabetic Nephropathy

  1999cited by this paper
• The Pro-Apoptotic Proteins, Bid and Bax, Cause a Limited Permeabilization of the Mitochondrial Outer Membrane That Is Enhanced by Cytosol

  1999cited by this paper
• The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

  1999cited by this paper
• High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells.

  1998cited by this paper
• BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases.

  1996cited by this paper
• The role of macrophages in diabetic glomerulosclerosis.

  1993cited by this paper
• Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus

  1990cited by this paper
• WKY Fatty Rat as a Model of Obesity and Non-insulin-dependent Diabetes Mellitus

  1990cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method

  year unknowncited by this paper

• Developmental origins of immunometabolic health

  2026cites this paper
• Retinal pigment epithelium-derived extracellular vesicles mediate outer blood retinal barrier disruption in response to AMD-related stress

  2025cites this paper
• Effects of sitagliptin and L-theanine combination therapy on testicular tissue in rats with experimental diabetes.

  2024cites this paper
• New Insights into the Pleiotropic Actions of Dipeptidyl Peptidase-4 Inhibitors Beyond Glycaemic Control

  2024cites this paper
• No Difference in Short-term Surgical Outcomes From Semaglutide Treatment for Type 2 Diabetes Mellitus After Cervical Decompression and Fusion

  2024cites this paper
• Sitagliptin ameliorates L-arginine-induced acute pancreatitis via modulating inflammatory cytokines expression and combating oxidative stress

  2024cites this paper
• Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax

  2024cites this paper
• Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic Mice

  2024cites this paper
• Incretin-based therapy: a new horizon in diabetes management

  2024cites this paper
• Protective effects of sitagliptin on methotrexate-induced nephrotoxicity in rats

  2023cites this paper
• Effect of Teneligliptin in comparison with Voglibose as an add on therapy in reducing microvascular complications in type II Diabetes Mellitus patients – A Prospective randomized control trial

  2023cites this paper
• Renoprotective Potency of Sitagliptin versus Pioglitazone in Type 2 Diabetic Patients: Impact on LncMIAT

  2023cites this paper
• Antioxidant and apoptotic activities of sitagliptin against hepatocellular carcinoma: An in vitro study

  2023cites this paper
• Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent

  2023cites this paper
• Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway

  2023cites this paper
• Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives.

  2022cites this paper
• Dipeptidyl peptidase IV inhibition delays developmental programming of obesity and metabolic disease in male offspring of obese mothers

  2022cites this paper
• Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy

  2022cites this paper
• The potential modulating impact of the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats

  2022cites this paper
• The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus

  2022cites this paper
• EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation

  2022cites this paper
• Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats.

  2021cites this paper
• Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis

  2021cites this paper
• Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong

  2021cites this paper
• Safety of Dipeptidyl Peptidase-4 Inhibitors in COVID-19: An Update

  2021cites this paper
• Sitagliptin's renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway

  2021cites this paper
• Maackiain Protects the Kidneys of Type 2 Diabetic Rats via Modulating the Nrf2/HO-1 and TLR4/NF-κB/Caspase-3 Pathways

  2021cites this paper
• A dipeptidyl peptidase IV inhibitory peptide relieves palmitic acid-induced endoplasmic reticulum stress in HepG2 cells independent of inhibiting dipeptidyl peptidase IV activity.

  2021cites this paper
• Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus

  2021cites this paper
• Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP-1-dependent nephrocyte apoptosis

  2021cites this paper
• Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats

  2021cites this paper
• The role of incretins and incretin-based drugs in autoimmune diseases.

  2021cites this paper
• Comparative effects of incretin-based therapy on early-onset diabetic nephropathy in rats: Role of TNF-α, TGF-β and c-caspase-3.

  2021cites this paper
• Hinokinin alleviates high fat diet/streptozotocin-induced cardiac injury in mice through modulation in oxidative stress, inflammation and apoptosis.

  2021cites this paper
• Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications.

  2021cites this paper
• Renoprotective Effects of DPP-4 Inhibitors

  2021cites this paper
• Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis

  2021cites this paper
• Effect of dipeptidyl peptidase‐4 inhibitors on complement activation

  2020cites this paper
• Crescent-Like Lesions as an Early Signature of Nephropathy in a Rat Model of Prediabetes Induced by a Hypercaloric Diet

  2020cites this paper
• Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.

  2020cites this paper
• The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes

  2020cites this paper
• Do DPP-4 Inhibitors Protect against COVID-19?

  2020cites this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cites this paper
• Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats.

  2020cites this paper
• Protective effect of sitagliptin and whole body gamma irradiation in diabetes-induced cardiac injury.

  2020cites this paper
• Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.

  2020cites this paper
• Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade

  2020cites this paper
• Diet‐induced rodent models of obesity‐related metabolic disorders—A guide to a translational perspective

  2020cites this paper
• Diet-Induced Rodent Models of Diabetic Peripheral Neuropathy, Retinopathy and Nephropathy

  2020cites this paper
• ReviewDiet-induced rodent models of diabetic peripheral neuropathy

  2020cites this paper
• Nephroprotective effect of Artemisia herba alba aqueous extract in alloxan-induced diabetic rats

  2020cites this paper
• Therapeutic Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19

  2020cites this paper
• Exendin-4 regulates Wnt and NF-κB signaling in lipopolysaccharide-induced human periodontal ligament stem cells to promote osteogenic differentiation.

  2019cites this paper
• Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells

  2019cites this paper
• Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes

  2019cites this paper
• Diabetic nephropathy: An update on pathogenesis and drug development.

  2019cites this paper
• Sphingosine kinase 1–interacting protein is a dual regulator of insulin and incretin secretion

  2019cites this paper
• Resistance Exercise Training Attenuates the Loss of Endogenous GLP-1 Receptor in the Hypothalamus of Type 2 Diabetic Rats

  2019cites this paper
• The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.

  2019cites this paper
• Effect of sitagliptin on tubulointerstitial Wnt/β‐catenin signalling in diabetic nephropathy

  2019cites this paper
• Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy.

  2019cites this paper
• THE EFFECT OF SITAGLIPTIN AND MIRABEGRON ON SERUM LEPTIN, ADIPONECTIN, TUMOR NECROSIS FACTOR-α AND OXIDATIVE STRESS IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

  2019cites this paper
• Involvement of brain natriuretic peptide signaling pathway in the cardioprotective action of sitagliptin

  2018cites this paper
• Impact of type 1 diabetes mellitus and sitagliptin treatment on the neuropeptide Y system of rat retina

  2018cites this paper
• Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes

  2018cites this paper
• The privileged position of glp-1 in diabetic nephropathy

  2018cites this paper
• Recombinant human GLP-1(rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats.

  2018cites this paper
• The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial

  2018cites this paper
• Sitagliptin Attenuates Endothelial Dysfunction of Zucker Diabetic Fatty Rats: Implication of the Antiperoxynitrite and Autophagy

  2018cites this paper
• Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection

  2018cites this paper
• Glucagon‑like peptide‑1 protects mouse podocytes against high glucose‑induced apoptosis, and suppresses reactive oxygen species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro.

  2018cites this paper
• Anagliptin prevents apoptosis of human umbilical vein endothelial cells by modulating NOX-4 signaling pathways.

  2018cites this paper
• Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy

  2018cites this paper
• Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

  2017cites this paper
• Cathepsin D plays a role in endothelial–pericyte interactions during alteration of the blood–retinal barrier in diabetic retinopathy

  2017cites this paper
• Diabetic Cardiomyopathy: Focus on Oxidative Stress, Mitochondrial Dysfunction and Inflammation

  2017cites this paper
• The ZDSD rat: a novel model of diabetic nephropathy.

  2017cites this paper
• Novel Therapies for Acute Kidney Injury

  2017cites this paper
• Treatment of diabetic kidney disease: current and future targets

  2017cites this paper
• Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling

  2017cites this paper
• DPP4 regulates the inflammatory response in a rat model of febrile seizures

  2017cites this paper
• Novel avenues for treating diabetic nephropathy: new investigational drugs

  2017cites this paper
• Anti-inflammatory drugs as promising cardiovascular treatments

  2017cites this paper
• High glucose stimulates cell proliferation and Collagen IV production in rat mesangial cells through inhibiting AMPK-KATP signaling

  2017cites this paper
• Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial

  2017cites this paper
• Effects of Incretin-Based Therapies on Diabetic Microvascular Complications

  2017cites this paper
• Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity

  2017cites this paper
• Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

  2017influential citation
• Sitagliptin exerts anti-apoptotic effect in nephrotoxicity induced by cisplatin in rats

  2017influential citation
• Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects

  2017cites this paper
• Sitagliptin reduces transforming growth factor-β1 and Platelet derived growth factor-BB in regulation of UAER in type 2 diabetic nephropathy stage III patients

  2017cites this paper
• Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease

  2017cites this paper
• Sitagliptin–Moringa oleifera coadministration did not delay the progression nor ameliorated functional and morphological anomalies in alloxan-induced diabetic nephropathy

  2017influential citation
• Терапия, основанная на инкретинах: почечные эффекты

  2016cites this paper
• Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

  2016cites this paper
• mTOR in Diabetic Nephropathy and Retinopathy

  2016cites this paper
• Lipopolysaccharides et glucagon-like peptide 1 : des mécanismes moléculaires à la physiopathologie

  2016cites this paper
• Obesity and brain inflammation: a focus on multiple sclerosis

  2016cites this paper
• Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury.

  2016cites this paper
• The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes

  2016cites this paper